Loading clinical trials...
Loading clinical trials...
Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study
Conditions
Interventions
IL2
Placebo
Locations
3
France
Centre d'investigation Clinique - Pitié salpêtrière
Paris, France
Centre d'investigation clinique Biothérapie Immunologie (CIC-BTi) - Groupe Hospitalier Pitié-Salpêtrière - AP-HP
Paris, France
Département des maladies du système nerveux et Centre d'investigation clinique - Groupe Hospitalier Pitié-Salpêtrière - AP-HP
Paris, France
Start Date
June 13, 2016
Primary Completion Date
October 11, 2019
Completion Date
June 15, 2020
Last Updated
November 9, 2020
NCT04047628
NCT04602390
NCT05978531
NCT04225312
NCT03536559
NCT05446285
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions